Martin-Castillo B - Search Results

1

A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study.

Martin-Castillo B, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Stradella A, Morilla I, Viñas G, Cortés J, Cuyàs E, Verdura S, Fernández-Ochoa Á, Fernández-Arroyo S, Segura-Carretero A, Joven J, Pérez E, Bosch N, Garcia M, López-Bonet E, Saidani S, Buxó M, Menendez JA. Martin-Castillo B, et al. Oncotarget. 2018 Nov 2;9(86):35687-35704. doi: 10.18632/oncotarget.26286. eCollection 2018 Nov 2. Oncotarget. 2018. PMID: 30479698 Free PMC article.

2

BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of breast cancer.

Brunet J, Vazquez-Martin A, Colomer R, Graña-Suarez B, Martin-Castillo B, Menendez JA. Brunet J, et al. Mol Carcinog. 2008 Feb;47(2):157-63. doi: 10.1002/mc.20364. Mol Carcinog. 2008. PMID: 17620310

3

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

Oliveras-Ferraros C, Vazquez-Martin A, López-Bonet E, Martín-Castillo B, Del Barco S, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Int J Oncol. 2008 Dec;33(6):1165-76. Int J Oncol. 2008. PMID: 19020749

4

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

Vázquez-Martín A, Oliveras-Ferraros C, del Barco S, Martín-Castillo B, Menéndez JA. Vázquez-Martín A, et al. Clin Transl Oncol. 2009 Jul;11(7):455-9. doi: 10.1007/s12094-009-0384-0. Clin Transl Oncol. 2009. PMID: 19574203 Review.

5

Incorporating the antidiabetic drug metformin in HER2-positive breast cancer treated with neo-adjuvant chemotherapy and trastuzumab: an ongoing clinical-translational research experience at the Catalan Institute of Oncology.

Martin-Castillo B, Dorca J, Vazquez-Martin A, Oliveras-Ferraros C, Lopez-Bonet E, Garcia M, Del Barco S, Menendez JA. Martin-Castillo B, et al. Ann Oncol. 2010 Jan;21(1):187-9. doi: 10.1093/annonc/mdp494. Epub 2009 Nov 2. Ann Oncol. 2010. PMID: 19884247 Free article. No abstract available.

6

Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.

Vazquez-Martin A, Fernandez-Real JM, Oliveras-Ferraros C, Navarrete JM, Martin-Castillo B, Del Barco S, Brunet J, Menendez JA. Vazquez-Martin A, et al. Int J Oncol. 2009 Dec;35(6):1369-76. doi: 10.3892/ijo_00000455. Int J Oncol. 2009. PMID: 19885560

7

Metformin and cancer: doses, mechanisms and the dandelion and hormetic phenomena.

Martin-Castillo B, Vazquez-Martin A, Oliveras-Ferraros C, Menendez JA. Martin-Castillo B, et al. Cell Cycle. 2010 Mar 15;9(6):1057-64. doi: 10.4161/cc.9.6.10994. Epub 2010 Mar 15. Cell Cycle. 2010. PMID: 20305377 Review.

8

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.

Vazquez-Martin A, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. Breast Cancer Res Treat. 2011 Apr;126(2):355-64. doi: 10.1007/s10549-010-0924-x. Epub 2010 May 11. Breast Cancer Res Treat. 2011. PMID: 20458531

9

Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with de novo resistance to trastuzumab (Herceptin).

Oliveras-Ferraros C, Vazquez-Martin A, Martin-Castillo B, Cufí S, Del Barco S, Lopez-Bonet E, Brunet J, Menendez JA. Oliveras-Ferraros C, et al. Biochem Biophys Res Commun. 2010 Jun 18;397(1):27-33. doi: 10.1016/j.bbrc.2010.05.041. Epub 2010 May 12. Biochem Biophys Res Commun. 2010. PMID: 20470755

10

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

Vazquez-Martin A, Oliveras-Ferraros C, Cufí S, Del Barco S, Martin-Castillo B, Menendez JA. Vazquez-Martin A, et al. J Cell Physiol. 2011 Jan;226(1):52-7. doi: 10.1002/jcp.22333. J Cell Physiol. 2011. PMID: 20658522

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page